Sanofi/Genzyme files Lemtrada at FDA for treatment of Multiple Sclerosis
Sanofi and its subsidiary Genzyme announced that the FDA has accepted for review the company�s supplemental Biologics License Application file seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing Multiple Sclerosis.
Genzyme expects FDA action on the application in the second half of 2013. Genzyme has already submitted its marketing authorization application for Lemtrada to the European Medicines Agency and the review process is underway. The Committee for Medicinal Products for Human Use opinion for Lemtrada is expected in Q2 2013.
115 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.